Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been assigned an average rating of “Moderate Buy” from the fifteen ratings firms that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $56.36.

Several research analysts recently commented on KYMR shares. HC Wainwright boosted their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. BMO Capital Markets started coverage on Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 price target on the stock. Wells Fargo & Company raised Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $38.00 to $57.00 in a research report on Monday, December 2nd. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Friday, December 27th. Finally, Citigroup started coverage on Kymera Therapeutics in a report on Thursday, March 13th. They issued a “buy” rating and a $52.00 price target for the company.

Kymera Therapeutics Stock Down 1.9 %

Kymera Therapeutics stock opened at $33.21 on Friday. Kymera Therapeutics has a twelve month low of $29.07 and a twelve month high of $53.27. The business has a fifty day moving average of $36.90 and a two-hundred day moving average of $42.44. The firm has a market cap of $2.16 billion, a P/E ratio of -14.19 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The company had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Equities analysts expect that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In related news, insider Ellen Chiniara sold 2,241 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the transaction, the insider now directly owns 80,085 shares in the company, valued at approximately $2,438,588.25. This trade represents a 2.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now owns 201,886 shares in the company, valued at approximately $6,147,428.70. This represents a 3.37 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,788 shares of company stock worth $455,202. Insiders own 15.82% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Several hedge funds have recently modified their holdings of KYMR. Blue Trust Inc. raised its holdings in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after purchasing an additional 270 shares during the period. State of Wyoming purchased a new position in shares of Kymera Therapeutics during the 4th quarter valued at approximately $45,000. GF Fund Management CO. LTD. acquired a new stake in Kymera Therapeutics in the 4th quarter valued at $55,000. KBC Group NV increased its holdings in Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after acquiring an additional 752 shares in the last quarter. Finally, Quarry LP acquired a new position in Kymera Therapeutics during the third quarter worth $95,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.